29 November 2022 - FDA decision based on new Phase 1b data.
Aravive today announced the US FDA has granted fast track designation to the company’s lead program, batiraxcept, for treatment of patients with advanced or metastatic clear cell renal cell carcinoma who have progressed after 1 or 2 prior lines of systemic therapy that include both immunooncology based and vascular endothelial growth factor tyrosine kinase inhibitor based therapies (either in combination or sequentially).